As an immunomodulator, RBAC can either up-regulate or down-regulate immune system activity as needed. In the case of immune insults, such as cancer or even the common cold, RBAC ramps up immune response. In the case of autoimmune diseases, where the immune system is overactive, a case study and anecdotal evidence indicates that RBAC has a calming effect. In addition to its immunomodulatory action, RBAC has anti-inflammatory and antioxidant activity. Studies also prove that the efficacy of RBAC does not decrease with prolonged use.
Acquired Immunodeficiency Syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV). As there is no known cure for AIDS, therapies that slow or halt the progression of the disease are the first line of defense. RBAC shows great promise in this area. An in vitro (test tube) study found that RBAC inhibited the replication of the virus in white blood cells extracted from HIV-positive patients. Additionally, RBAC increased the number of T (both helper and cytotoxic) and B cells. The results of this in vitro study are supported by anecdotal evidence that RBAC increases T cell levels and reduces the virus load. This means that not only does RBAC have direct anti-HIV activity – it may also boost the host’s immune response.
Natural killer (NK) cells are the body’s first line of defense against pathogens and cancer. They attach themselves to the cancer cell membrane and inject granules that cause the cell’s death within five minutes. Human clinical research in patients with breast cancer, prostate cancer, leukemia and multiple myeloma shows that RBAC increases the activity of NK cells by 300% on average, often leading to long-term stabilization or remission of the disease when used in conjunction with conventional treatment. Additionally, several studies have shown that RBAC improves the quality of life of late-stage cancer patients. One study in particular, performed at a cancer clinic in Japan, evaluated the effect of RBAC on stage III and IV cancer patients over a two-year period. In the study, 109 patients were treated with the clinic’s standard complimentary alternative medicines and 96 patients were administered RBAC in addition to the standard treatment. The RBAC group had a statistically significant improvement in quality of life and a 50% increase in survival rate.
Many in vitro and human clinical trials have shown that RBAC increases the activity of natural killer (NK) cells, the body’s first line of defense against pathogen invasion. RBAC also multiplies counts of B and T lymphocytes and supports the body’s production of cytokines, making it a potent immune activator. One study in elderly adults found that those who took RBAC were much less susceptible to the common cold than patients who took a placebo. Among those taking RBAC who did get sick, the therapy cut the duration of common cold symptoms in half.
Chronic rheumatism is a type of autoimmune disease which triggers an inflammatory response that promotes tissue destruction. One small human clinical study found that administration of RBAC improved symptoms – such as pain, poor sleep, swelling and decreased appetite – as well as quality of life in patients with rheumatism. Because of its ability to selectively down-regulate immune system activity, it is expected that RBAC may benefit other autoimmune conditions as well.
Inflammation is a response of the immune system that is intended to protect the body against pathogens. Unfortunately, sometimes inflammation can become sustained, causing tissue damage and even organ dysfunction. Recent studies show that inflammation is a causative factor to a number of diseases, including cancer and heart disease. Because RBAC is a proven anti-inflammatory, it may help prevent heart disease and other diseases where inflammation plays a role.